ImmuneShield Biotech

Pioneering immune harmony through innovative cell-free immunomodulatory products for medical devices and beyond

Contact Us

Our Vision: Achieving Immune System Harmony

ImmuneShield's vision is to enable immune system tolerance without compromising immune defense. We are pioneering a transformative approach to one of modern medicine's most critical challenges: achieving harmony between the body's natural defenses and life-saving medical interventions.

This vision encompasses breakthrough solutions for medical device biocompatibility, organ transplantation, and autoimmune regulation. By leveraging the natural immunomodulatory power of Wharton's Jelly mesenchymal stromal cells, we're creating a future where patients can benefit from advanced medical technologies without the burden of chronic inflammation, device failure, or systemic immunosuppression.

Our approach represents a paradigm shift in how we think about immune regulation—moving from suppression to sophisticated modulation that preserves protective immunity while preventing harmful responses.

Executive Summary

ImmuneShield Biotech is pioneering a revolutionary class of cell-free immunomodulatory products derived from Wharton's Jelly mesenchymal stromal cells (WJMSC) secretome and extracellular vesicles (EVs). Our breakthrough platform addresses one of the most persistent challenges in modern medicine: the foreign body response to implantable and blood-contacting medical devices.

Our proprietary Wharton's Jelly-derived secretome platform strategically modulates macrophage and fibroblast behavior, dramatically reducing fibrosis and inflammatory responses while actively promoting tissue integration. This biological matrix can be formulated as a coating, hydrogel, or absorbable envelope, making it seamlessly compatible with existing device manufacturing processes and sterilization protocols.

The clinical implications are profound: by developing immune-quieting surfaces and matrices that minimize immune system activation against medical devices, we enhance durability, improve clinical performance, and deliver better patient outcomes. Our technology platform has the potential to transform the medical device industry while opening pathways to applications in transplantation, autoimmune disease, and regenerative medicine.

The Medical Device Challenge

Immune Reactivity Bottleneck

Medical devices revolutionize patient care, yet immune reactivity remains a fundamental limitation that constrains device performance and longevity across all categories.

Fibrosis and Encapsulation

Chronic inflammation, fibrotic encapsulation, and tissue scarring undermine device longevity, leading to diminished functionality and premature failure.

Foreign Body Reaction

The foreign body response remains a primary driver of revision surgeries, creating patient burden and escalating healthcare costs across multiple device categories.

Integration Challenges

Biofilm formation and poor tissue integration limit the performance and clinical utility of next-generation implants and advanced medical devices.

Our Solution

Biological coatings and formulations that quiet the immune system without compromising natural defenses, enabling breakthrough device performance and patient outcomes.

The Science Behind ImmuneShield

01

WJMSC: Natural Immunomodulator

Wharton's Jelly mesenchymal stromal cells represent nature's solution to immune regulation. The secretome contains a sophisticated array of bioactive factors including IL-10, TGF-β, CD274 (PD-L1), VEGF, HGF, EGF, PDGF-AA, ICAM-1, and VCAM-1. These components work synergistically to create an immune-permissive microenvironment that promotes healing while preventing excessive inflammatory responses.

02

Mechanisms of Action

Our secretome platform operates through multiple complementary mechanisms: it dampens pro-inflammatory M1 macrophage activation while promoting the healing M2 phenotype, reduces fibroblast-driven fibrosis that leads to device encapsulation, enhances endothelial and epithelial repair for improved integration, supports angiogenesis for vascular in-growth, and facilitates natural tissue integration around implants.

03

Versatile Formats

ImmuneShield's technology can be deployed in multiple product formats to address diverse clinical applications: sprayable coatings for device surfaces, injectable hydrogels for tissue applications, perfusates for organ preservation and transplantation, and impregnated liners for surgical applications. This versatility enables broad market applicability and rapid product development.

Value Proposition for MedTech Partners

Complement Engineering Excellence

ImmuneShield complements your existing engineering and materials expertise with next-generation biological modulation capabilities that enhance device performance without requiring redesign.

Enhanced Biocompatibility

Dramatically improve biocompatibility profiles and device durability, extending functional lifespan and reducing revision rates across your product portfolio.

Product Differentiation

Create differentiated, premium next-generation device lines that command market leadership and support enhanced pricing based on superior clinical outcomes.

Regulatory Advantages

Enable new regulatory claims for reduced inflammation and fibrosis, supporting marketing differentiation and competitive positioning in crowded markets.

Portfolio Expansion

Expand your device portfolios through combination product innovation, opening new market segments and revenue streams with enhanced value propositions.

Regulatory and Manufacturing Strategy

Regulatory Pathway

Classification: Combination products requiring coordination between FDA CBER/CDRH in the US and EMA ATMP-MDR hybrid pathways in Europe.

Biocompatibility: Complete ISO 10993 framework compliance demonstrating safety across all relevant biological endpoints for device applications.

Clinical Strategy: Phased development with initial focus on lower-risk applications, building regulatory precedent for expanded indications.

Manufacturing Approach

Production: GMP-compliant WJMSC secretome production through partnership with PBKM, Europe's largest stem cell bank with proven manufacturing capabilities.

Stability: Lyophilized format ensuring compatibility with standard ethylene oxide (EtO) sterilization processes used throughout the medical device industry.

Scalability: Process designed for commercial-scale manufacturing with clear pathway to cost-effective production at volume.

Preclinical Validation Framework

1

Animal Models

Orthopedic defect models testing bone integration, cardiac stent injury models evaluating vascular applications, and robotic bowel repair models assessing surgical adhesion prevention.

2

Key Endpoints

  • Fibrous capsule thickness measurement
  • M1/M2 macrophage ratio quantification
  • Neointimal thickness assessment
  • Adhesion scoring systems
  • Biomarker analysis
3

Milestone Target

Complete 6-month GLP studies for each primary indication, generating robust safety and efficacy data supporting regulatory submissions and partner discussions.

Strategic Approach and Core Aims

1

Immune Stabilization

Innovating to quiet and stabilize the immune system, achieving immune accommodation and long-term tolerance while preserving protective immunity.

2

Asset Development

Defining and advancing specific high-value assets from within our broad technology platform, prioritizing medical device applications with clear commercial pathways.


3

Transplant Applications

Enhancing long-term organ and tissue acceptance with reduced rejection, improving transplant compatibility by minimizing fibrosis and chronic rejection.

Longer-Term Vision

  • Controlling autoimmunity while preserving protective immunity
  • Enhancing post-procedure health outcomes
  • Expanding into regenerative medicine applications

WJMSC Platform Overview

Proprietary Bioengineered Platform

Our technology platform is based on bioengineering advanced products from Wharton's Jelly Mesenchymal Stem Cells (WJMSCs), their Extracellular Vesicles (EVs), and complete secretome. This cell-free approach eliminates concerns about cell viability, tumorigenicity, and immune rejection associated with whole-cell therapies.

Rich Factor Profile

Extremely abundant in growth factors and immunomodulatory cytokines that orchestrate tissue healing and immune regulation.

Low Immunogenicity

Minimal immunogenic potential combined with potent immunomodulatory capacity creates an ideal therapeutic profile.

Versatile Applications

Platform enables diverse product formats and application routes across multiple therapeutic areas and device categories.

Strategic Partnerships and Infrastructure

1

Corporate Structure

ImmuneShield Biotech fully incorporated as U.S.-based C Corporation with governance structure designed for growth and investor protection.

2

PBKM Collaboration

Joint venture with Polish Stem Cell Bank (PBKM), Europe's largest stem cell bank, providing manufacturing capabilities and expertise in WJMSC secretome bioengineering.

3

CRO Partnership

Active discussions with Charles River Laboratories for preclinical study design and execution, leveraging world-class expertise in regulatory toxicology and efficacy testing.

4

Manufacturing Collaboration

Anticipated partnership with Velico for protein spray drying expertise, ensuring scalable and cost-effective manufacturing of lyophilized product formats.

5

Scientific Advisory Board

World-class scientific advisory board taking shape with leaders in transplant immunology, regenerative medicine, and medical device development.

Anticipated Applications and Outcomes

Targeted Immune Regulation

Quiets the immune system in a precise, localized manner without systemic immunosuppression, maintaining protective immunity while preventing device rejection and fibrosis.

Personalized Medicine

Fulfills the promise of personalized medicine by enabling tailored immune modulation based on individual patient needs and specific device applications.

Bridging Disciplines

Successfully bridges regenerative medicine and bioengineering, combining the best of biological innovation with advanced materials science.

Enhanced Safety Profile

Demonstrably safer and more effective than current immunosuppressive approaches, with minimal systemic effects and preserved immune function.

Flexible Administration

Multiple administration routes including infusion, topical ointment, film, spray coating, preservation solution, and machine perfusion for organ storage.

Broad Therapeutic Potential

Wide-ranging therapeutic applications spanning autoimmune diseases, solid organ transplantation, cell therapy support, and cancer immunotherapy modulation.

Competitive Advantages

Novel Technology

First-in-class approach to immune modulation for medical devices

Proven Safety

Cell-free format with inherent safety advantages

Personalization Ready

Platform enables customized formulations

Multiple Applications

Versatile platform across device categories

Minimal Toxicity

Natural biological components with excellent tolerability

IP Protection

Comprehensive patent filed with USPTO

Manufacturing Scale

Partnership providing clear scalability pathway

Paradigm Shifting

Potential to transform medical device performance

Execution Roadmap: Key Actions in Parallel

Initial Proof-of-Concept

Skin grafting experiments in ACI-Lewis strain rats demonstrating un-immunosuppressed survival of approximately 7 days post-transplant, establishing baseline for product testing.

Product-Enhanced Studies

Repeat skin grafting experiments in the presence of ImmuneShield/PBKM product to demonstrate extended survival and improved graft quality.

Strategic Partnerships

Collaborations and scientific advisory board composition progressing rapidly with key opinion leaders committed to project success.

Publication Strategy

Comprehensive publication plan developed to establish scientific credibility and thought leadership in peer-reviewed journals.

IP Landscape

Patent landscape thoroughly analyzed and understood, with strategic filing approach to maximize protection and freedom to operate.

Regulatory Strategy

Regulatory development pathway clearly defined in consultation with experts in combination products and device coatings.

Clinical Development

Clinical development strategy outlined with clear milestones and decision points supporting efficient capital deployment.

Scientific Foundation

Design and hypothesis built on substantial prior work and deep domain expertise in transplant immunology and regenerative medicine.

Proof-of-Concept Timeline

Month 1: Preparation Phase

  • PBKM secretome production from 5 validated Wharton's Jelly donors
  • Comprehensive characterization using MAGPIX multiplex detection system
  • Initial analytical profiling of cytokine and growth factor content
  • Protocol finalization with Charles River Laboratories

Month 6: Completion Phase

  • Concentrated product development via spray drying technology
  • Complete murine skin transplant study execution
  • Multiple treatment arm comparison and analysis
  • Final data compilation and statistical analysis
  • Regulatory documentation and study report preparation

The study design compares control group (punch biopsy and skin graft only) with groups receiving optimal immunosuppression, ImmuneShield product treatment, and combination of suboptimal immunosuppression plus ImmuneShield product. Primary endpoints include graft survival duration, tissue quality assessment, inflammatory marker profiles, and fibrosis quantification.

Leadership Team

Dr. Prakash Rao

Co-Founder

Dr. Rao is an alumnus of the prestigious Indian Institute of Science and the world-renowned Starzl Transplant Institute at the University of Pittsburgh. As a trained transplant immunologist with more than 30 years of experience in clinical laboratory diagnostics, he brings deep expertise in clinical and transplant immunology, regenerative medicine, and laboratory medicine.

Dr. Rao is a Fellow of the American College of Healthcare Executives (FACHE) and has published extensively in peer-reviewed journals on transplant immunology and immune regulation. His vision and scientific leadership have been instrumental in defining ImmuneShield's innovative approach to immune modulation.

Jamie Taylor, MBA

Co-Founder

Jamie brings extensive biopharma experience with leadership roles spanning strategy, finance, and operations at multiple life sciences companies including Johnson & Johnson. Her expertise in commercialization, business development, and strategic planning positions ImmuneShield for successful growth and partnership development.

In recent years, Jamie has advised early-stage, small- and mid-cap biotech companies with a focus on autoimmune disease therapeutics. She serves as an appointed lecturer in Health Economics at the MIT Sloan School of Management and at Yale University. Jamie holds an MBA from Northwestern's Kellogg School of Management, an M.A. from Harvard University, and a B.A. with Distinction from the University of Virginia.

Market Opportunity and Business Model

Near-Term Market Focus

ImmuneShield's initial commercial strategy targets high-value medical device applications where immune-related complications create significant clinical and economic burden. The cardiac device market, orthopedic implants sector, and surgical mesh category represent immediate opportunities with clear unmet needs and established regulatory pathways.

Our business model centers on strategic partnerships with established medical device companies who will integrate ImmuneShield technology into their existing product lines. This approach enables rapid market entry, leverages partner manufacturing and distribution capabilities, and generates revenue through licensing fees, milestone payments, and royalties on product sales.

Long-Term Expansion Strategy

Beyond medical devices, our platform technology opens pathways into transplantation (organ preservation and tolerance induction), cell therapy support (CAR-T microenvironment optimization), and autoimmune disease management. Each application area builds on our core competency in immune modulation while addressing distinct market needs with substantial commercial potential.

Risk Mitigation and Success Factors

1

Technical Risk

Risk: Secretome efficacy may vary between donors or not translate to human applications.

Mitigation: Five-donor pooled product ensures consistency; animal model selected for translational relevance; dose-response studies built into protocol.

2

Manufacturing Risk

Risk: Scale-up challenges from research to commercial production.

Mitigation: Partnership with PBKM provides proven GMP manufacturing; spray drying technology is well-established; early process development work underway.

3

Regulatory Risk

Risk: Combination product pathway may encounter unexpected hurdles.

Mitigation: Early FDA and EMA engagement planned; precedent exists for similar biologics; experienced regulatory consultants retained.

4

Partnership Risk

Risk: Device companies may be slow to adopt novel technology.

Mitigation: Multiple target partners identified; clear value proposition with clinical and economic benefits; advisory board includes industry leaders.

5

Competitive Risk

Risk: Competitors may enter the space or develop alternative approaches.

Mitigation: Strong IP position with broad claims; first-mover advantage in device applications; ongoing patent landscape monitoring.

6

Market Risk

Risk: Market adoption may be slower than projected.

Mitigation: Targeting high-value applications with clear unmet needs; building clinical evidence early; engaging key opinion leaders.

Investment Summary and Use of Funds

Funding Request

ImmuneShield is raising $2.5 million in seed financing to complete proof-of-concept studies, advance regulatory strategy, strengthen intellectual property protection, and prepare for strategic partnerships with leading medical device companies. This funding will take the company through major value-inflection milestones that substantially de-risk the technology and position ImmuneShield for Series A financing or strategic partnership agreements.

Key Milestones

Months 1-6

Complete proof-of-concept studies with statistically significant efficacy data; initiate discussions with target device partners.

Months 7-12

File additional patent applications; complete manufacturing process development; publish initial results in peer-reviewed journals.

Months 13-18

Advance partnership discussions; complete regulatory strategy for lead indication; prepare IND-enabling studies.

Months 19-24

Secure strategic partnership or initiate Series A fundraising; begin expanded preclinical studies for additional indications.

Join Us in Revolutionizing Medical Device Performance

A Clear Opportunity to Transform Patient Outcomes

ImmuneShield Biotech stands at the forefront of a paradigm shift in medical device technology. Our innovative approach to immune modulation addresses fundamental challenges that have constrained device performance for decades, offering the potential to dramatically improve patient outcomes while creating substantial value for strategic partners and investors.

We have assembled a world-class team with deep expertise in transplant immunology, regenerative medicine, and biopharma commercialization. Our strategic partnerships provide manufacturing capabilities and regulatory expertise, while our intellectual property position offers robust protection in a market space with minimal competition.

The path forward is clear: complete proof-of-concept studies, establish partnerships with leading device companies, and expand our platform technology into adjacent high-value applications. We invite you to join us in this transformative journey as we work to save and improve lives through innovative immune modulation.

Contact Information

Email

praoenator@gmail.com

Phone

(+1) 504-913-2729

Location

McKinney, Texas, USA